ClinicalTrials.gg
CompletedNCT07030439Updated Jun 22, 2025

A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State

A Phase 1 interventional study of Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. and Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. in Solid Tumor, sponsored by Impact Therapeutics, Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Impact Therapeutics, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 years 10 months after the study started (first participant enrolled Jul 2021, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

An Open-label, Randomized, Single-dose, Two-way Crossover Study to Compare the Bioequivalence of Senaparib 10 mg Capsules Manufactured at Different Manufacturing Sites After Administration in Fasting State in Healthy Chinese Subjects

Read the detailed description

An Open-label, Randomized, Single-dose, Two-way Crossover Study to Compare the Bioequivalence of Senaparib 10 mg Capsules Manufactured at Different Manufacturing Sites After Administration in Fasting State in Healthy Chinese Subjects.

32 Subjects are planned to be enrolled. At least, 26 subjects are planned to be completed.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Impact Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects fully understood the purpose, nature, methods and possible adverse reactions of the trial, voluntarily participated in the trial, and signed an form before any trial procedure, and promised to participate in all procedure of the trial.
  2. Healthy Chinese male subjects aged 18 to 55 (inclusive) at screening.
  3. (BMI) ranged from 19.0 to 26.0 kg/m2 (inclusive); body weight ≥ 50.0 kg.
  4. Subjects could communicate well with the investigators and understood and abided by the requirements of this trial.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with diseases with clinical abnormality, including but not limited to disease concerning nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolic system and skeletal system.
  2. Subjects with allergic history (including drug and food allergies, etc.).
  3. Subjects with history of dysphagia or any gastrointestinal disease that affected drug absorption judged by the investigator.
  4. Subjects who had received surgery within 3 months before screening, or planned to have surgery during the trial, or those who had previous surgery that would affect drug absorption (e.g. gastrectomy).
  5. Subjects who could not tolerate venipuncture, or had a history of needlesickness and fainting at the sight of blood.
  6. Subject with lactose intolerability (who having had milk diarrhea).
  7. Subjects who had drug abuse history within 6 months before screening, or had a positive urine drug screening (screening or baseline period) result.
  8. Subjects who consumed more than 14 units of alcohol per week (1 unit of alcohol = 360 mL beer, 150 mL wine, or 45 mL liquor) within 3 months before screening, or who had a positive result of alcohol breath test (screening or baseline period), or could not give up alcohol during the trial.
  9. Subjects who consumed an average of more than 5 cigarettes per day within 3 months before screening, or who could not stop using any tobacco products during the trial.
  10. Subjects who consumed an average of excessive amounts of tea, coffee and / or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months before screening.
  11. Subjects who had participated in clinical trials of other study drugs/devices within 3 months before the first dose of the drug, or had participated in 3 or more clinical trials of drugs/devices in the past year; if other study drugs had a longer half-life, the time interval would be longer and was required to be 5 half-lives of the drug.
  12. Subjects who donated blood including blood component or had massive blood loss (≥ 200 mL), or received blood transfusion or used blood products and blood biological products within 3 months before screening.
  13. Subjects who received within 4 weeks before screening.
  14. Subjects who had taken any drugs [such as: barbiturates, carbamazepine, phenytoin, , omeprazole; SSRI(selective serotonin reuptake inhibitor) antidepressants, cimetidine, macrolides, sedative hypnotics, antihistamines, antivirals (such as saquinavir), calcium antagonists (such as diltiazem, verapamil), rifamycins (such as rifampicin)] that potently inhibit or induce enzymes within 28 days before the use of the investigational drug. If the past drug used had a longer half-life, the time interval would be longer and was required to be 5 half-lives of the drug, e.g., phenobarbital required a 5-week .
  15. Subjects who had taken prescription drugs, over-the-counter drugs, dietary supplements or Chinese herbal medicine within 14 days before the first dose of the investigational drug. If the past drug used had a longer half-life, the time interval would be longer and was required to be 5 half-lives of the drug. Limited use of over-the-counter drugs that were not considered to affect the overall outcome of the study was allowed on a case-bycase basis after approval by the sponsor and the investigator.
  16. Any test result of surface antigen, hepatitis B core antibody, virus antibody, (HIV) antibody, or treponema pallidum antibody was positive.
  17. At screening, vital signs (blood pressure, pulse and body temperature) examination, comprehensive physical examination and laboratory tests (hematology, blood biochemistry, urinalysis) indicated abnormal results with clinical significance according to the investigator. The reference normal range of vital signs (including the cut-off value) was as follows: Sitting systolic blood pressure was 90 to 140 mmHg, diastolic blood pressure was 60 to 90 mmHg, pulse was 60 to 100 bpm, body temperature (ear temperature) was 35.7 to 37.9°C. The specific situation was comprehensively determined by the investigator.
  18. At screening, the interval (corrected by Fridericia's formula, QTcF = QT/RR1/3) > 450 msec or QRS complex > 120 msec was obtained by 12-lead in supine position in resting state (at least 5 min). If QTc was more than 450 msec or QRS was more than 120 msec, ECG measurement should be repeated twice, and the average value of QTc or QRS measured three times was judged by the investigator as abnormality with clinical significance.
  19. Subjects who were allergic to Senaparib, or to any ingredients of the preparation.
  20. Vigorous exercise could not be avoided within 48 h before the first dose of the investigational drug and during the trial.
  21. Subjects who consumed any food or beverages containing alcohol, caffeine, chocolate, or rich in xanthine within 48 h before the first dose of the investigational drug; or those who could not abstain from these products during the trial.
  22. Subjects who could not abstain from grapefruit or grapefruit-related citrus (eg, pomelo) or juice within 7 days before the first dose of investigational drug and during the trial.
  23. Subjects or its partners who had birth plan, or were unwilling to adopt effective methods, or had sperm donation plan throughout the trial and within 90 days after the last dose of the investigational drug.
  24. Subjects who were unwilling or unable to follow the lifestyle guidelines described in the study protocol (such as dietary restrictions and activity requirements).
  25. Subjects who had other acute or chronic medical or psychiatric diseases, which may increase the risks of participating in this trial, or may interfere with the interpretation of the trial results, were judged unsuitable to participate in this trial by the investigator.
  26. Subjects judged by the investigator to be unsuitable for participation in the trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Senaparib capsules first new manufacturing site then original manufacturing site

    A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) in second intervention period (after washout period: at least 7 days)

    Drug: Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. · Drug: Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd.

  • Experimental
    Senaparib capsules first original manufacturing site then new manufacturing site

    A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) in second intervention period (after washout period: at least 7 days)

    Drug: Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. · Drug: Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd.

Interventions

  • A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) in second intervention period (after washout period: at least 7 days)

  • A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) in second intervention period (after washout period: at least 7 days)

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum concentration

    Time frame: 0-72 hour

  2. AUC0-last

    Area under the curve from time 0 to the last time with quantifiable concentration

    Time frame: 0-72 hour

  3. AUC0-inf

    If the data were available, area under the curve from time 0 to infinity

    Time frame: 0-72 hour

07

Study locations

1 site
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Oct 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 22, 2025
StartActual
Jul 18, 2021
Primary completionActual
Oct 12, 2021
CompletionActual
Oct 12, 2021
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07030439
Lead sponsor
Impact Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Jul 18, 2021
Primary completion
Oct 12, 2021
Completion
Oct 12, 2021
Last update
Jun 22, 2025

Study contacts

Chuanling Li
principal investigator · Xuzhou Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Senaparib

Start the discussion